Augusto Cezar Santomauro

Augusto Cezar Santomauro

Auto-generated profile, based on publicly available information

Augusto Cezar Santomauro

BP—A Beneficência Portuguesa de São Paulo (BP), São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2023 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
ASAugusto Cezar Santomauro
Augusto Cezar Santomauro
ÁMÁurea Luiza Fernandes Magalhães
Áurea Luiza Fernandes Magalhães
FMFlávia Tedesco Motta
Flávia Tedesco Motta
LSLucas Santos de Santana
Lucas Santos de Santana
PFPedro Campos Franco
Pedro Campos Franco
MTMilena G. Teles
Milena G. Teles
Background: A maturity-onset diabetes of the young (MODY) calculator has been described and validated for use in European Caucasians. This study evaluated its performance in Brazilians diagnosed with diabetes mellitus (DM) before 35 years of age. Methods: The electronic records of 391 individuals were reviewed in 2020 at the diabetes clinic of a quaternary hospital in São Paulo were analyzed: 231 with type 1 DM (T1DM), 46 with type 2 (T2DM) and 114 with MODY. The MODY calculator was applied to the three groups. A receiver operating characteristic curve was calculated to obtain cut-off points for this population. Results: The principal differences between the MODY and the T1DM and T2DM groups were body mass index, a positive family history of diabetes and mean HbA1c level. Age at diagnosis in the MODY group was only significantly different compared to the T2DM group. Specificity and sensitivity were good for the cut-off points of 40%, 50% and 60%, with the accuracy of the model for any of these cut-off points being > 95%. Conclusion: The capacity of the calculator to identify Brazilian patients with MODY was good. Values ≥ 60% proved useful for selecting candidates for MODY genetic testing, with good sensitivity and specificity.

23 December 2022 in Clinical Genetics
Verified
Journal Article
Closed access
ACAline Dantas Costa‐Riquetto
Aline Dantas Costa‐Riquetto
LSLucas Santos de Santana
Lucas Santos de Santana
PFPedro Campos Franco
Pedro Campos Franco
AJAugusto Cezar Santomauro Jr
Augusto Cezar Santomauro Jr
AMArtur Eduardo Martio
Artur Eduardo Martio
MTMilena G. Teles
Milena G. Teles

19 June 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
PFPedro Campos Franco
Pedro Campos Franco
MPMichelle Patrocinio
Michelle Patrocinio
ACAline Dantas Costa-Riquetto
Aline Dantas Costa-Riquetto
ASAugusto Cezar Santomauro
Augusto Cezar Santomauro
LGLarissa Garcia Gomes
Larissa Garcia Gomes
MTMilena G. Teles
Milena G. Teles
SUMMARY Familial partial lipodystrophy (FPLD) is a very rare genetic disease characterized by insulin resistance due to a loss of subcutaneous fat from the extremities together with a progressive storage of fat around the face and neck and inside the abdomen. In over 50% of cases, molecular genetic testing reveals pathogenic variants in two nuclear genes, LMNA and PPARG. The case reported here refers to a woman phenotypically diagnosed with FPLD, who presented with diabetes and multiple cervical lipomatosis and [...] SUMMARY Familial partial lipodystrophy (FPLD) is a very rare genetic disease characterized by insulin resistance due to a loss of subcutaneous fat from the extremities together with a progressive storage of fat around the face and neck and inside the abdomen. In over 50% of cases, molecular genetic testing reveals pathogenic variants in two nuclear genes, LMNA and PPARG. The case reported here refers to a woman phenotypically diagnosed with FPLD, who presented with diabetes and multiple cervical lipomatosis and

24 October 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
PFPedro Campos Franco
Pedro Campos Franco
AJAugusto Cezar Santomauro Jr
Augusto Cezar Santomauro Jr
ACAline Dantas Costa-Riquetto
Aline Dantas Costa-Riquetto
LSLucas Santos de Santana
Lucas Santos de Santana
LGLarissa Garcia Gomes
Larissa Garcia Gomes
MTMilena Gurgel Teles
Milena Gurgel Teles
Background To improve the precision of molecular diagnosis by means of a comprehensive bidirectional phenotypic and genotypic reanalysis in cases of unresolved monogenic diabetes previously investigated using a targeted next-generation sequencing (tNGS) panel. Methods Molecular and clinical data from 128 unresolved cases referred between 2011 and 2019 were analyzed. These included 92 cases of suspected maturity-onset diabetes of the young (MODY), 12 of neonatal diabetes, 16 of familial partial lipodystrophy (FPLD), 7 of mitochondrial diabetes, and 1 of Wolfram syndrome. All cases were initially investigated using a tNGS panel consisting of 51 nuclear genes and the complete mitochondrial genome. Results This extensive reanalysis process increases molecular diagnosis from 9 to 22%. Phenotypic reevaluation, entailing in-depth phenotyping, is instrumental in excluding 62 atypical cases (48.4%). Genotypic reanalysis identifies 5 previously overlooked molecular defects: two mutations in regulatory regions (one in the HNF1A promoter and another in the PTF1A enhancer); one in the MTTK mitochondrial gene; one in the MFN2 gene; and one in the GCK gene. Conclusions Our findings indicate that a combined approach of genotypic and, mainly, phenotypic reanalysis is an effective strategy for improving the accuracy of molecular diagnosis in individuals with suspected monogenic diabetes.

14 July 2026 in medRxiv
Verified
Preprint
Open access
ÂBÂngela Bersch-Ferreira
Ângela Bersch-Ferreira
RPRaira Pagano
Raira Pagano
DFDanielle Cristina Fonseca
Danielle Cristina Fonseca
TOThatiane Lopes Valentim Di Paschoal Ostolin
Thatiane Lopes Valentim Di Paschoal Ostolin
AFAna Laura Fogaça
Ana Laura Fogaça
ACAdriano Namo Cury
Adriano Namo Cury
Type 2 diabetes (T2D) affects more than 16 million Brazilians and has nearly doubled in the last 20 years. Lifestyle interventions reduce T2D incidence in people at risk of developing the disease; however, no large-scale trials have evaluated diabetes prevention programs in Brazil or compared telehealth and hybrid delivery in middle-income settings. These are key gaps that must be addressed to enable nationwide scale-up, particularly in primary care settings and remote areas. This article presents the protocol for the PROVEN-DIA trial, designed to address these evidence gaps. PROVEN-DIA is a multicenter, open-label, randomized controlled superiority trial with a parallel design enrolling 1,305 adults with prediabetes at 30 sites across all five Brazilian regions (ClinicalTrials.gov: NCT06426277 ). Participants will be randomly assigned in equal numbers to one of three groups. All groups receive lifestyle guidance targeting diet, physical activity, sleep, stress, alcohol consumption, and smoking, in accordance with Brazilian national guidelines. The two intervention groups receive PROVEN-DIA, a structured 36-month lifestyle program with 43 scheduled contacts encompassing individual counseling sessions, structured support contacts, and group education sessions, delivered either in a hybrid format (PROVEN-DIA) or telehealth only (TelePROVEN-DIA). The control group receives the same lifestyle guidance through unstructured individual visits every six months, without predefined content or ongoing support. The primary outcome is the cumulative incidence of type 2 diabetes at 36 months. Secondary outcomes include body weight, fasting glucose, glycated hemoglobin (HbA1c), dietary quality, physical activity, sedentary behavior, sleep quality, perceived stress, alcohol consumption, smoking behavior, and health-related quality of life. Analyses will follow the intention-to-treat principle.